Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1975 Jul;21(1):82–96.

Observations in immunotherapy of lymphoma and melanoma patients.

J W Thomas, I H Plenderleith, D V Clements, S Landi
PMCID: PMC1538246  PMID: 1102163

Abstract

Maintenance of remission solely by repeated BCG vaccinations in seven patients with non-Hodgkin's lymphoma who had achieved a complete clinical remission with initial standard therapy has provided sufficient encouragement to begin a randomized clinical trial. In vitro lymphocyte responses to mitogens and PPD used as parameters of cell-mediated immunity have not proved to be of value in predicting early or late recurrence in six pre-trial and trial patients. Eight out of twenty-one patients with malignant melanoma have shown a satisfactory clinical response (10-34 months) to immunotherapy. Those who respond must show immunological reactivity to the stimulating agent, however the best clinical responses were not associated with the highest degrees of in vivo and in vitro sensitization. The skin reactivity and the in vitro lymphocyte response to PPD as well as a 2-3-fold increase in the appearance of colony-forming units in the peripheral blood following the intratumour injection of BCG or PPD are helpful in prognosis and management of these patients. All patients with malignant melanoma who presented with a PHA response less than 40% of normal made a poor response to immunotherapy. Autopsies performed on seven patients dying with extensive melanocarcinomatous disease failed to show any serious adverse toxic reactions or infections from oral and intratumour injections of BCG.

Full text

PDF
82

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amiel J. L. Immunothérapie active non spécifique par le B.C.G. de la leucémie virale E male G2 chez desreceveurs isogéniques. Rev Fr Etud Clin Biol. 1967 Nov;12(9):912–914. [PubMed] [Google Scholar]
  2. Bain B., Lowenstein L. Effect of glass and plastic culture tubes on the mixed leukocyte reaction. J Lab Clin Med. 1968 Jun;71(6):1045–1048. [PubMed] [Google Scholar]
  3. Beard M. E., Fairley G. H. Acute leukemia in adults. Semin Hematol. 1974 Jan;11(1):5–24. [PubMed] [Google Scholar]
  4. Evans R., Alexander P. Mechanism of immunologically specific killing of tumour cells by macrophages. Nature. 1972 Mar 24;236(5343):168–170. doi: 10.1038/236168a0. [DOI] [PubMed] [Google Scholar]
  5. Hunt J. S., Silverstein M. J., Sparks F. C., Haskell C. M., Pilch Y. H., Morton D. L. Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet. 1973 Oct 13;2(7833):820–821. doi: 10.1016/s0140-6736(73)90860-x. [DOI] [PubMed] [Google Scholar]
  6. Israel L., Mugica J., Chahinian P. Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin test. Biomedicine. 1973 Feb 10;19(2):68–72. [PubMed] [Google Scholar]
  7. Janossy G., Greaves M. F. Lymphocyte activation. II. discriminating stimulation of lymphocyte subpopulations by phytomitogens and heterologous antilymphocyte sera. Clin Exp Immunol. 1972 Mar;10(3):525–536. [PMC free article] [PubMed] [Google Scholar]
  8. Kurnick J. E., Robison W. A. Clony growth of human peripherl white blood cells in vitro. Blood. 1971 Feb;37(2):136–141. [PubMed] [Google Scholar]
  9. LEMONDE P., CLODE M. Effect of BCG infection on leukemia and polyoma in mice and hamsters. Proc Soc Exp Biol Med. 1962 Dec;111:739–742. doi: 10.3181/00379727-111-27908. [DOI] [PubMed] [Google Scholar]
  10. Lemonde P., Clode-Hyde M. Influence of bacille Calmette-Guérin infection on polyoma in hamsters and mice. Cancer Res. 1966 Apr;26(4):585–589. [PubMed] [Google Scholar]
  11. Mathé G., Amiel J. L., Schwarzenberg L., Schneider M., Cattan A., Schlumberger J. R., Hayat M., De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697–699. doi: 10.1016/s0140-6736(69)92648-8. [DOI] [PubMed] [Google Scholar]
  12. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  13. OLD L. J., BENACERRAF B., CLARKE D. A., CARSWELL E. A., STOCKERT E. The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 1961 Oct;21:1281–1300. [PubMed] [Google Scholar]
  14. Thomas J. W., Clements D., Grzybowski S. In vitro lymphocyte responses and skin test reactivity following BCG vaccination. Clin Exp Immunol. 1971 Nov;9(5):611–623. [PMC free article] [PubMed] [Google Scholar]
  15. Zbar B., Bernstein I. D., Rapp H. J. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971 Apr;46(4):831–839. [PubMed] [Google Scholar]
  16. Zbar B., Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science. 1971 Apr 16;172(3980):271–273. doi: 10.1126/science.172.3980.271. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES